TY - JOUR
T1 - Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1
AU - Mengele, Karin
AU - Napieralski, Rudolf
AU - Magdolen, Viktor
AU - Reuning, Ute
AU - Gkazepis, Apostolos
AU - Sweep, Fred
AU - Brünner, Nils
AU - Foekens, John
AU - Harbeck, Nadia
AU - Schmitt, Manfred
PY - 2010/7
Y1 - 2010/7
N2 - In cancer, the serine protease urokinase-type plasminogen activator, its inhibitor (plasminogen activator inhibitor type-1) and the receptor (CD87), among other proteolytic factors, are involved in tumor cell dissemination and turnover of the extracellular matrix. Unsurprisingly, a battery of very uniform data, amassed since the end of the 1990s, has put these members of the plasminogen activation system into the forefront of prognostic/predictive cancer biomarkers relevant to predict the clinical course of cancer patients and their response to cancer therapy. The present review focuses on the molecular characteristics of the disease forecast biomarkers urokinase-type plasminogen activator and plasminogen activator inhibitor type-1, and techniques to quantitatively assess these cancer biomarkers, in the context of potential clinical application and personalized disease management.
AB - In cancer, the serine protease urokinase-type plasminogen activator, its inhibitor (plasminogen activator inhibitor type-1) and the receptor (CD87), among other proteolytic factors, are involved in tumor cell dissemination and turnover of the extracellular matrix. Unsurprisingly, a battery of very uniform data, amassed since the end of the 1990s, has put these members of the plasminogen activation system into the forefront of prognostic/predictive cancer biomarkers relevant to predict the clinical course of cancer patients and their response to cancer therapy. The present review focuses on the molecular characteristics of the disease forecast biomarkers urokinase-type plasminogen activator and plasminogen activator inhibitor type-1, and techniques to quantitatively assess these cancer biomarkers, in the context of potential clinical application and personalized disease management.
KW - clinical utility
KW - malignant solid tumor
KW - molecular characteristics
KW - plasminogen activator system
KW - predictive impact
KW - prognostic relevance
KW - quantitative assessment
UR - http://www.scopus.com/inward/record.url?scp=78649269236&partnerID=8YFLogxK
U2 - 10.1586/erm.10.73
DO - 10.1586/erm.10.73
M3 - Review article
C2 - 20964613
AN - SCOPUS:78649269236
SN - 1473-7159
VL - 10
SP - 947
EP - 962
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
IS - 7
ER -